Active Biotech AB Interim Report January - March 2013

LUND, SWEDEN--(Marketwired - April 25, 2013) -

Laquinimod

· first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of relapsing-remitting multiple sclerosis

· data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment

Tasquinimod

· the Phase III study is proceeding according to plan

ANYARA

· Phase II/III study in renal cell cancer concluded

· Results presented:

- study did not achieve primary clinical endpoint

- doubling of progression-free survival and overall survival in 25 percent of patients

- planning of the continued clinical development ongoing

57-57 (paquinimod)

· clinical trial in systemic sclerosis concluded, evaluation underway

ISI

· focus on submission of patents

Other information

· Active Biotech raised SEK 270 M through a directed share issue to Investor

 Jan - Mar Jan - Dec (SEK M) 2013 2012 2012 --------------------------------------------------------------- * Net sales 2.4 2.6 227.9 * Operating loss -77.0 -100.7 -163.2 * Net loss -78.0 -99.0 -175.0 * Earnings per share (SEK) -1.10 -1.44 -2.54 

This report is also available at www.activebiotech.com

Active Biotech AB : Interim Report January - March 2013: http://hugin.info/1002/R/1695994/558366.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1695994]